Snoretox to Present at Leading Global Veterinary Conferences in 2026

Snoretox has been selected to present our recently published research at two of the world’s most prestigious veterinary conferences: the ACVIM Forum (Seattle, June 2026) and the ECVS Annual Scientific Meeting (Liverpool, July 2026).

These internationally recognised meetings bring together leading veterinary specialists and represent the highest standards of clinical and scientific excellence. Acceptance is competitive and reflects the quality and growing relevance of Snoretox’s work. Presenting at both forums marks an important milestone for the company and highlights its increasing recognition within the global veterinary community.

‘The Veterinary Journal’ publishes our ground breaking research.

Clinical observations of tetanus toxin plus decoy, Snoretox-1, a novel targeted stimulant, in a pilot study of 6 British Bulldogs with BOAS’
Anthony Sasse, Luke J. Norbury, Thomas McLean, Maurice Newport, Arthur House, David W. Swift, Danny Aliano, Peter M. Smooker, Russell Conduit.

Click here to read the full article.

Click here to download the full article.

Click here to see the dog video results.

Spontaneous media reporting of one of our trial participants: Courtesy of the Herald Sun Article by Anna Shreeves (photo by Jason Edwards)

Breathing easier? Snore thing!

You’ve heard of Botox but it’s time to be introduced to Snoretox, a potentially life-changing drug for dogs that struggle to breathe properly.

This seven-year-old pug, Pugtato, has brachycephalic obstructive airway syndrome, an affliction that often affects the breed.

For many of these flat-faced dogs, there has been no way to remedy their breathing, until now.

A clinical trial led by Dr Arthur House at Peninsula Vet Emergency & Referral Hospital with RMIT University chose Pugtato as its test subject.

Following some preliminary tests, the pug received two injections of Snoretox. Two months on, the effects are said to be remarkable.

Joanna Herceg, Pugtato’s owner and founder of Pug Rescue Victoria, said his improvement had been “overwhelmingly drastic.”

Before Snoretox, he was an “agitated” dog that would struggle to settle. Now, she can barely recognise him. His energy has increased, he is breathing well and he seems like an all-round contented dog.

“I will try to do everything for these dogs, and it’s heartbreaking to watch them suffer from not being able to breathe properly,” Ms Herceg said.

“He has gone from an unadoptable dog to a really awesome adoptable dog.”

pugrescue.org.au

Snoretox Wins the 2025 Innovation Award at the Animal Health Summit in Kansas City

Snoretox has won the Emerging Companies Competition at the Animal Health Summit in Kansas City. This summit is the leading deal-making event for veterinary pharmaceutical companies in the USA. The judges selected us unanimously (6 out of 6). We continue to attract a high level of interest, and new opportunities are opening up. This award has both supported this momentum and added value to our company.

Selected to present at KC Animal Health Summit August 2025

Snoretox is excited to be selected to participate in the Emerging Company Presentations at the KC Animal Health Summit August 2025

Kansas City is home to the Animal Health Corridor. Because of its significant animal health industry concentration, the Corridor offers a uniquely supportive environment for early-stage entrepreneurs in the animal health, nutrition, diagnostic and technology industry.

14 applicants were selected across all areas from 43 applicants.

https://kcanimalhealth.thinkkc.com/events/animal-health-summit

Help us help BOAS dogs

We’ll send you news and ways to be involved in giving BOAS dogs a better life.